enzo tramontano

IAAASS 2018 Program

 IAAASS 2018 Program  Commenti disabilitati su IAAASS 2018 Program
Gen 272020
 

Download the abstract book: 4th IAAASS ABSTRACT-BOOK

2018.09.24 
5.00 pm  Registration
6.00 pm                  Remarks
EnzoTramontano Organizing Committee Coordinator
Giorgio Palù President  of the European Society for Virology and of the Società Italiana di Virologia Italian Society for Virology – SIV-ISV
José Esté President of the International Society for Antiviral Research
Inaugural Lecture  
José Esté Host-pathogen interactions and antiviral drug potency
Fundaciò Irsicaixa (Spain)
2018.09.25
9.00 am                 Plenary lectures 
Stephan Ludwig Structural Targeting signal transduction pathways to fight the flu
University of Münster, Germany
Stuart Le Grice Small molecule targeting of viral RNA regulatory elements
National Cancer Institute (USA)
11.00-11.15 am Coffee Break
11.15 am  Plenary lectures 
Andrea Brancale Computer-aided design of novel antivirals
Cardiff University (UK)
Giorgio Palù Functionality and druggability of the E6 oncoprotein of HPV
University of Padova
1.00-2.00 pm Lunch
2.00-3.30 pm Poster session 1
3.30-5.00 pm Selected oral communications 
6.00 pm Coffee break
6.30-7.30 pm          Discussion groups 
2018.09.26 
9.00 am Plenary lectures 
Raffaele De Francesco From the elucidation of HCV life-cycle to the development of highly effective antivirals

INGM, Italy

Vincenzo Summa Discovery of Grazoprevir an HCV pangenotype protease inhibitor approved for interferon free therapy to cure  the HCV infected patients
IRBM (Italy)
11.00-11.15 am Coffee Break
11.15 am Round table: Working in a company after the PhD 

Timothy Tellinghuisen (Hoffmann-La Roche)

Vincenzo Summa (IRBM)

Stuart Le Grice (NCI)

Franco Lori (Virostatics)

1.00-2.00 pm Lunch
2.00-3.30 pm Poster session and Bio-tech companies presentation desk  
3.30-5.00 pm Selected oral communications 
6.00 pm Coffee break
6.30-7.30 pm          Discussion groups 
2018.09.27
9.00 am Plenary lectures 
Zlatko Janeba The progress in development of inhibitors of viral reverse transcriptase
University of Prague, Czech Republic
Michelle Hastings Therapeutic Targeting of Gene Expression with Antisense
Rosalind Franklin University, USA
11.00-11.15 am Coffee Break
11.15 am  Plenary lectures 
Reuben Harris Targeting Evolvability
University of Minnesota (USA)
Maurizio Botta Antiviral compounds with broad spectrum activity on enveloped viruses
University of Siena (Italy)
1.00 pm Lunch
Free afternoon
2018.09.28
9.00 am  Plenary lectures 
Thomas Mertens Re-emergence of antibodies in antiviral therapy
University of Ulm (Germany)
Daniel Appella Disrupting HIV Nucleocapsid Protein with Mercaptobenzamides
NIH (USA)
11.00-11.15 am Coffee Break
11.15 am  Plenary lectures 
Graciela Andrei Viral DNA polymerases: effects of amino acid substitutions on viral adaptation and evolution
KU Leuven (Belgium)
Simona Distinto In silico virtual screening approaches for antiviral drug discovery
University of Cagliari (Italy)
1.00-2.00 pm Lunch
2.00-3.00 pm Poster session 
3.00-5.00 pm Selected oral communications 
6.00 pm Coffee break
6.30-7.30 pm          Discussion groups 
2018.09.29
                                            Breakfast and leaving

IAAASS 2018 Participants

 IAAASS 2018 participants  Commenti disabilitati su IAAASS 2018 Participants
Gen 272020
 

4th IAAASS participants

Name Surname Affiliation e-mail
Graciela Andrei KU Leuven, Belgium graciela.andrei@rega.kuleuven.be
Daniel Appella NIH, USA appellad@niddk.nih.gov
Maurizio Botta University of Siena, Italy maurizio.botta@unisi.it
Andrea Brancale Cardiff University, UK brancalea@cardiff.ac.uk
Angela Corona University of Cagliari, Italy angela.corona@unica.it
Raffaele De Francesco National Institute of Molecular Genetics, Italy defrancescoraffaele@ingm.org
Simona Distinto University of Cagliari, Italy simonadistinto@gmail.com
José Esté Fundacia Irsicaixa, Badalona, Spain jaeste@irsicaixa.es
Reuben Harris University of Minnesota, USA, rsh@umn.edu
Michelle Hastings Rosalind Franklin University, USA michelle.hastings@rosalindfranklin.edu
Zlatko Janeba Czech Academy of Sciences , Czech Republic zlatko.janeba@uochb.cas.cz
Stuart F. J. Le Grice NCI, Frederick, MD, USA legrices@mail.nih.gov
Franco Lori Virostatics, Italy f.lori@virostatics.com
Stephan Ludwig University of Münster, Germany ludwigs@uni-muenster.de
Elias Maccioni University of Cagliari, Italy maccione@unica.it
Thomas Mertens Ulm University, Germany thomas.mertens@uni-ulm.de
Giorgio Palù University of Padova, Italy giorgio.palu.unipd@gmail.com
Cristina Parolin University of Padova, Italy cristina.parolin@unipd.it
Vincenzo Summa IRBM, Italy v.summa@irbm.it
Timothy L. Tellinghuisen F.Hoffmann-La Roche Ltd, Switzerland timothy.tellinghuisen@roche.com
Enzo Tramontano University of Cagliari, Italy tramon@unica.it
Surname Name Affiliation e-mail
Biolatti Matteo University of Turin, Italy matteo.biolatti@unito.it
Boccuto Adele University of Siena, Italy adele.boccuto@gmail.com
Botwina Paweł Jagiellonian University, Poland pawel.botwina@doctoral.uj.edu.pl
Castanon Velasco Oscar Harvard Medical School, USA castanon.o@gmail.com
Criscuolo Elena Vita-Salute San Raffaele University, Italy criscuolo.elena@hsr.it
Dąbrowska Agnieszka Jagiellonian University, Poland agnieszka.dabrowska@doctoral.uj.edu.pl
De Forni Davide Virostatics, Italy d.deforni@virostatics.com
Deplano Serenella University of Cagliari, Italy seredeplano@gmail.com
Dragoni Filippo University of Siena, Italy dragonifilippo@gmail.com
Duarte Peñaloza Luisa Fernanda Pontificia Universidad Católica de Chile, Chile lfduarte@uc.cl
Ermellino Laura University of Cagliari, Italy lauraerm94@gmail.com
Esposito Francesca University of Cagliari, Italy francescaesposito@unica.it
Falsitta Lucia University of Siena, Italy falsitta@student.unisi.it
Fanunza Elisa University of Cagliari, Italy elisafanunza@unica.it
Garcia-Vidal Edurne IrsiCaixa AIDS Research Institute , Spain egvidal@irsicaixa.es
Giangeri Ginevra Univeristy of Padua, Italy ginevra.giangeri@gmail.com
Grandi Nicole University of Cagliari, Italy nicole.grandi2@gmail.com
Griffante Gloria University of Turin, Italy gloria.griffante@gmail.com
Gupta Vivek Kumar University of Allahabad, India vivekguptaau@gmail.com
Hakobyan Astghik National Academy of Science, Armenia a_hakobyan@mb.sci.am
Jassey  Alagie Taipei Medical University, Taiwan alagie_jassey@yahoo.com
Kumar Avneesh Faculty of Veterinary Science, Mathura (UP) avi4you@gmail.com
Lin Liang-Tzu Taipei Medical University, Taiwan ltlin@tmu.edu.tw
Liu Ching-Hsuan (Julia) Taipei Medical University, Taiwan julia.chliu@gmail.com
Manocha Ekta University of Brescia, Italy e.manocha@unibs.it
Meleddu Rita University of Cagliari, Italy rita.meleddu@unica.it
Nannetti Giulio Cardiff University, UK nannettig@cardiff.ac.uk
Pagani Isabel San Raffaele University, Italy pagani.isabel@hsr.it
Pisano Maria Paola University of Cagliari, Italy mp.pisano@hotmail.it
Pujantell Maria IrsiCaixa AIDS Research Institute, Spain mpujantell@irsicaixa.es
Pulkkinen Lauri University of Helsinki, Finland lauri.ia.pulkkinen@helsinki.fi
Riva Valentina IGM-CNR Pavia, Italy valentina.riva01@universitadipavia.it
Ryabchevskaya Ekaterina Moscow State University, Russia eryabchevskaya@gmail.com
Singh Saumya Sam Higginbottom University of Agriculture Technology & Sciences, India singh.saumya0406@gmail.com
Singh Harvijay Indian Institute of Technology Roorkee, India harvijay.iitr@gmail.com
Statzu Maura Sapienza University of Rome, Italy maura.statzu@uniroma1.it
Tocco Graziella University of Cagliari, Italy toccog@unica.it
Tseligka Eirini University of Geneva, Switzerand eirini.tseligka@unige.ch
Verachi Francesca University of Rome Tor Vergata, Italy francesca.verachi@gmail.com
Wang Jonathan Taipei Medical University, Taiwan wang.ying.jonathan@gmail.com
Wong Shu Hui (Joanne) Taipei Medical University, Taiwan shwong93@gmail.com

 

2018 Speakers

 IAAASS 2018 speakers  Commenti disabilitati su 2018 Speakers
Gen 272020
 

 

GRACIELA ANDREI holds a PhD in Biological Sciences and is an Assistant Professor at the Faculty of Medicine, Katholieke Universiteit Leuven, Belgium. At the Rega Institute for Medical Research, Department of Microbiology and Immunology, she carries out her research work that is mainly focused on chemotherapy of viral diseases, with emphasis on herpesviruses (cytomegalovirus, varicella-zoster virus and herpes simplex), poxviruses (vaccinia, cowpox, orf), polyomaviruses and papillomaviruses, and the study of the molecular mechanisms underlying the antiviral drug resistance phenomenon and anticancer activity of nucleotide analogues. Dr. G. Andrei has authored approximately 30 and co-authored approximately 260 papers in international peer-reviewed journals between 1983 and 2011. She has also (co)authored 6 book chapters and 10 proceedings articles and about 260 published abstracts between 1983 and 2011.

 

DANIEL APPELLA was graduated from the University of Wisconsin-Madison, 1998, with Ph.D. in Organic Chemistry. He continued with a postdoc at MIT, also working in the area of organic chemistry. He was an assistant professor at Northwestern University, in the Chemistry  Department, from 2001 to 2004. In 2005 he moved to NIH as a tenure track PI, promoted to tenure at NIH in 2008. Currently, he is Chief of the Synthetic Bioactive Molecules Section, one of the labs in the Laboratory of Bioorganic Chemistry that is part of the National Institute of Diabetes and Digestion and Kidney Diseases (NIDDK). Appella’s laboratory research uses synthetic organic chemistry to create new molecules with unique biological activity with the potential to evolve into a new strategy for diagnosing or treating a disease. Within their research, most of the time goes for the molecules synthesis, and the use of a large amount of molecular modeling and biophysical techniques to study the molecules they make. Different projects of the Appella’s group are: A) exploration of the incorporation of carbocyclic rings and sidechains into the backbone of several different peptide nucleic acids (PNAs) in order to provide the basis for design of PNA-based sensors and to develop new diagnostic techniques based on our modified PNAs; B) examination of sidechain-bearing polyamines as molecular scaffolds for the display of RNA binding groups, in order to develop syntheses of these polyamines, making combinatorial libraries of these molecules, and studying their binding properties to two important RNA targets (TAR RNA and RRE RNA of HIV); C) inspired by a recent identification of a few novel molecules that reactivate mutant p53 to bind its DNA target, the 3rd research topic is to design a new class of molecules that reactivate mutant p53 in order to probe the unique mechanism that allows small organic molecules to restore normal activity to a mutant protein.

MAURIZIO BOTTA graduated with honors in chemistry at the University of Rome in 1974. After his military service he returned to work at the Institute of Organic Chemistry, University of Rome with the title of Fellow , under the guidance of Prof. R. Nicoletti . In 1977 he started at the University of New Brunswick (Canada) , a period of research under the guidance of Prof. K. Wiesner , earning his PhD in November 1979 . Since December 1979 resumed scientific and educational cooperation with Prof. R. Nicoletti at the University of Rome becoming a researcher . Winner of a bag NATO in 1985, he traveled for a year in laboratories of Prof. S. Hanessian of the ‘ University of Montreal (Canada) , as invited researcher .In October 1987 as an Associate Professor of Pharmaceutical Chemistry , he has held the chair of Analysis Pharmaceutical Chemistry III of the Degree Course in Pharmaceutical Chemistry and Technology of Faculty of Pharmacy, University of Siena and Bioorganic Chemistry for substitution at the Faculty of Mathematical, Physical and Natural Sciences. In the periods July-September 1987 – July September 1988 and from November to January 1989 he was Invited Professor at the University of Montreal (Canada). Since 2000 he is Full Professor of Pharmaceutical Chemistry at the University of Siena and holds the task of teaching Complements of Medicinal Chemistry and Synthesis and Design of Drugs for the Master of Science in Pharmaceutical Chemistry , University of Siena. In years 2002-2008 he held the position of Director of the Department of Drug Chemistry and Technology University of Siena. Prof. Botta was a member of the Board of the Division of Pharmaceutical Chemistry Society Italian Chemical from 1998 to 2004 , Director of the School ‘s annual ” Laboratory Methods Synthetic Medicinal Chemistry ” organizer of the workshop ” European Workshop on Drug  Design ” , now in its seventh edition and ‘ ” European Workshop in Drug Synthesis ” , at the University of Siena and he  is also a member of ‘ editorial board of scientific journals such as ” ChemMedChem ” , “Current Pharmaceutical Design” and ” Journal of Medicinal Chemistry ” . Since January 2008 he is Adjunct Professor at Temple University ‘s College of Science and Technology in Philadelphia (USA). The research group of Prof. Botta, currently consists of about 30 young people between undergraduates , graduate students,research grant and a single researcher , is active in the synthesis and structure determination of biologically active natural products , organic synthesis and testing of potential agents anti-viral and anti-cancer , anti-tuberculosis and synthesis of antifungal compounds . The techniques used to these studies can be summarized in conventional techniques for organic synthesis , synthesis techniques for small molecules in the solid phase , the use of enzymes , microwaves , and parallel synthesis, also  molecular modeling techniques , such as docking , molecular dynamics , QSAR and 3D QSAR Virtual screening , generation of virtual libraries are used for the discovery and optimization of potential drugs . Recently, next to the chemical synthesis and Computational has also added the analytical chemistry for the determination of parameters Pharmacokinetic necessary for the optimization of pharmacologically active molecules . The scientific production of Professor Botta is summed up in about 460 publications in journals International , 15 patents and more than 150 conference papers .

ANDREA BRANCALE is a Professor in Medicinal Chemistry at Cardiff University. He undertook his PhD and postdoctoral work in synthetic medicinal chemistry under Professor Chris McGuigan, focusing on the design and synthesis of novel nucleosides and nucleotides as potential anticancer and antiviral drugs. With his appointment as lecturer in the Cardiff School of  Pharmacy and Pharmaceutical Sciences he strategically directed his research interests on the use of computer-aided techniques to design and discover novel anti-viral and anti-cancer compounds. In 2017, he was promoted to Professor and he continued to establish his reputation as an internationally recognised drug design expert in the antiviral and anticancer field. He is author on more than 130 peer-review papers and actively collaborates with several academic groups in the UK and the rest of the world. His focus to drug discovery and development emerges also from his strong connection with the private sector. He was a scientific consultant for the NASDAQ listed biotech Synergy Pharmaceuticals and for the NASDAQ listed biotech Inhibitex. He is an elected Board member of the International Society for Antiviral Research. In 2013, he was presented with the Young Researcher William Prusoff Award for his contribution to the antiviral field. Currently, he is also the Editor-in-Chief of Antiviral Chemistry and Chemotherapy

RAFFAELE DE FRANCESCO completed his studies in Biology in 1984 at the University of Milan. Subsequently, he was a postdoctoral fellow in the Biochemistry Department at Emory University, Atlanta, U.S.A., and in the Gene Expression Program at the European Molecular Biology Laboratory, Heidelberg, Germany. Between 1991 and 2008, Raffaele De Francesco worked at I.R.B.M./Merck Research Laboratory in Rome (Italy), where he led a group focusing on the identification of molecular targets for antiviral therapy and the development HCV enzymes inhibitors as novel agents for the treatment chronic hepatitis C. In 2008, he joined INGM as a Sr Group Leader. RDF is internationally recognized primarily for his pioneering work on the molecular virology of the hepatitis C virus (HCV) and for his key contributions to antiviral drug discovery and understanding of resistance to antiviral drugs. His early work in this area was pivotal in the identification of what became the most successful molecular targets of the new direct antivirals for HCV. In recognition of these contributions, RDF was assigned the 2018 EMBL Alumni Lennart Philipson Award. His current research interests focus on the identification of novel strategies for the eradication of chronic viral infection, such as chronic HBV and HIV infections. RDF has more than 140 papers published in peer-reviewed journal and a H-index of 64 (Scopus) and is inventor in many international patents.

SIMONA DISTINTO graduated in Pharmaceutical Chemistry at the University of Cagliari in 2003 and in 2003 won the “IN TIME 36” fellowship at the Athlone Laboratories, Ireland. She finished in 2006 her Ph.D. in Technology and Legislation of Drugs and Bioactive Molecules at University of Cagliari. From 2006 to 2008 she was post-Doc fellow at University of Catanzaro and then at  University of Innsbruck. From 2008 to 2010 she was  Senior Application Scientist at Inte:ligand Software- GmbH, the company that held and constantly develops the Inte:Ligand Software Entwicklungs und Consulting GmbH that supports scientists worldwide with innovative approaches for early drug discovery research by developing and applying computer-aided design (CAD) solutions. In  2008- 2009 Simona Distinto was Assistant Professor University of Innsbruck, nd from 2009 to 2011 Young Researcher FIRB University of Catanzaro, form 2010-2011 Adjunct Professor University of Catanzaro and from 2012 to 2016 Assistant Professor University of Cagliari. Form 2017 to present she is Associate Professor of medicinal chemistry at the University of Cagliari where she is leading the Computer Aided Drug    Design Section of the Department of Life and Environmental Sciences. Her expertise is mainly directed towards the field of computational medicinal chemistry. She has several undergoing projects based on the application of different approaches to the virtual screening and rational design of new drugs directed towards several targets, mainly involved in viral infections, cancer therapy and neurodegenerative diseases.  Simona Distinto  is co-autor of 55 scientific papers and collaborates as reviewer of several leading journals of Pharmaceutical Chemistry.

JOSE ESTE is a Senior Researcher and Head of the HIV Pathogenesis Laboratory of the AIDS Research Institute-IrsiCaixa, Hospital Germans Trias i Pujol in Badalona (Barcelona), Spain. He received a BSc. degree in Biology from University of Western Ontario, a Masters degree in Biochemistry from the Venezuelan Institute of Scientific Research and a PhD degree in Medical Science from the Katholieke Universiteit Leuven. Jose’s research interests include virus-cell interactions, HIV entry, antiviral drug-resistance, antiviral drug design and evaluation. His group also provides support to clinical trials in the HIV Unit of Hospital Germans Trias i Pujol. José Esté is the president of the International Society for Antiviral Research (ISAR), he is an editor for Antiviral Research and is on the editorial boards of the Journal of Biological Chemistry and Antimicrobial Agents and Chemotherapy. José Esté has coauthored over 160 peer-reviewed publications and review articles and serves in different Spanish and international review boards and evaluation committees.

REUBEN HARRIS Dr. Harris is a Professor of Biochemistry, Molecular Biology and Biophysics, the Associate Director of the Institute for Molecular Virology, and a Member of the Masonic Cancer Center at the University of Minnesota. He received his B.S. (1993) and Ph.D. (1997) degrees from the University of Alberta and performed postdoctoral work at Baylor College of Medicine (1997-1998), Yale University (1998), and Cambridge University (1998-2003). He joined the University of Minnesota as an Assistant Professor in 2003 and was promoted to Associate Professor with Tenure in 2008 and to Full Professor in 2013. Dr. Harris has received numerous grants and awards, including a Searle Scholarship, membership to the American Academy of Microbiology, and a Distinguished McKnight University Professorship. In 2015, he was also appointed as a Howard Hughes Medical Institute Investigator. Dr. Harris is an Associate Editor for Science Advances and an Editorial Board Member for Journal of Biological ChemistryJournal of Virology, and Cancer Research. He has published over 160 manuscripts, contributed to 13 patent applications, and co-founded a cancer therapeutics company. Dr. Harris’s scientific passion is elucidating mechanisms of mutation and establishing relevance to human biology and disease. As a doctoral student, he discovered a novel recombination-dependent mutation process operative in stationary-phase bacteria with implications for antibiotic resistance and microbial evolution. As a postdoctoral fellow, he helped solve an immunology Rosetta stone by discovering the DNA cytosine deaminase activity of AID and proposing a DNA deamination model for antibody gene diversification. Also as a postdoctoral fellow, he discovered the DNA cytosine deaminase activity of several APOBEC family members and, during the transition to faculty, elucidated a new mechanism of antiviral immunity by demonstrating APOBEC3G-catalyzed retroviral cDNA hypermutation. As a Principal Investigator, Dr. Harris has become known for his work on APOBEC enzymes in antiviral immunity, including discovering multiple APOBEC3s in HIV-1 restriction, demonstrating the mechanism by which HIV-1 Vif degrades APOBEC3 proteins, and elucidating the first structures of APOBEC-ssDNA and APOBEC-RNA complexes. This body of work has shed light on fundamental mechanisms of antiviral immunity and yielded new strategies for drug development. In recent years, Dr. Harris’s virology studies have also enabled a major breakthrough in cancer research. His group found that APOBEC3B and APOBEC3H are responsible for a large proportion of mutations in breast, head/neck, lung, bladder, cervical, and other cancers. Independent work has confirmed these results and indicated that “APOBEC mutagenesis” far exceeds most other sources of mutations in cancer, including those attributable to smoking and UV rays. This breakthrough has created new opportunities for cancer diagnosis, prognosis, and treatment by targeting tumor evolvability. Please see http://harris.cbs.umn.edu for more information on Dr. Harris’s research program.

MICHELLE HASTINGS. Dr. Michelle Hastings, Ph.D., is an Associate Professor of Cell Biology and Anatomy and Director of the Center for Genetic Diseases at the Chicago Medical School at Rosalind Franklin University of Medicine and Science. Dr. Hastings earned an undergraduate degree in biology from St. Olaf College and a Ph.D. in biology/genetics from Marquette University.  She was a postdoctoral and senior fellow at Cold Spring Harbor Laboratory before joining the faculty at the Chicago Medical School at Rosalind Franklin University where she is currently the Director of the Center for Genetic Diseases and an Associate Professor of Cell Biology and Anatomy. Dr. Hastings’ lab studies RNA splicing and the ways this process can go wrong in disease and can be therapeutically manipulated. In particular, she studies RNA processing in neurodegenerative disease including Batten disease, spinal muscular atrophy, Usher syndrome, Alzheimer’s and Parkinson’s disease. A major focus of her work is on developing therapeutic approaches to treat these disorders using antisense technology. Her studies on Usher syndrome led to the first demonstration that hearing can be recovered in mice with a mutation that causes congenital deafness in humans.

ZLATKO JANEBA earned his Ph.D. in Organic chemistry from the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague, part of the Czech Academy of Sciences. He underwent postdoctoral research training in the groups of Prof. Morris J. Robins at Brigham Young University and Prof. Paul F. Torrance at Northern Arizona University. He spend 3 years (March 2005 – February 2008) as senior scientist at Moravek Biochemicals, Inc. in California, one of the leading companies in the field of custom synthesis of radiolabeled compounds for pharmaceutical research. In 2008 he rejoined the research team of Prof. Antonín Holý at IOCB and in March 2010 he established his Junior Research Group at the same institution. Since January 2016, he is the head of the Senior Research Group at IOCB. Current research of the group involves design, synthesis and SAR studies of modified nucleosides and nucleotides, as well as other heterocyclic compounds, with a wide range of biological properties, especially antiviral, anticancer, antibacterial, anti-parasitic, and anti-inflammatory. Co-author of about 80 research papers with some 770 citations, h-index 16 (WoS), several patents. Member of International Society for Antiviral Research (ISAR), International Society of Nucleosides, Nucleotides and Nucleic Acids (IS3NA) and International Society of Heterocyclic Chemistry (ISHC). Dr. Janeba is an associate editor of Antiviral Chemistry & Chemotherapy and serves as a Vice-chairman of the IOCB Supervisory board and of the Supervisory board of IOCB TTO.

STUART LE GRICE received his Ph.D. from the Department of Biochemistry, University of Manchester, UK, in 1976, where he studied the mechanisms of R-factor-mediated multidrug resistance in Escherichia coli. After postdoctoral training in the United Kingdom, Germany, and the United States, he was appointed Senior Scientist in the Central Research Units of Hoffmann La Roche, Basel, Switzerland, where he worked from 1984 to 1990 evaluating HIV-1 and HIV-2 enzymes as therapeutic targets. In 1990, he joined the faculty in the Division of Infectious Diseases, Department of Medicine, Case Western Reserve University (CWRU), Cleveland, OH. Initially recruited as an Associate Professor of Medicine, he was awarded tenure in 1992, and in 1995 was promoted to Professor of Medicine, Biochemistry, and Oncology. From 1994 to 1999, he served as Director of the NIH-funded CWRU Center for AIDS Research. Dr. Le Grice joined the National Cancer Institute in 1999 as Chief of the Resistance Mechanisms Laboratory in the HIV Drug Resistance Program, Center for Cancer Research (CCR), and in 2005 was appointed to the Senior Biomedical Research Service. In 2006, he was appointed Head of the Center of Excellence in HIV/AIDS & Cancer Virology, CCR. He is a member of the CCR HIV and Cancer Virology faculty, Chemistry and Biology faculty, and the Steering Committee of the Molecular Targets Discovery Program. In addition to serving on the Editorial Board of the Journal of Biological Chemistry, Dr. Le Grice has been an ad hoc (1990-1999) and permanent Study Section member of NIH AIDS review panels (2000-2004), as well as an ad hoc reviewer for several international funding agencies.

STEPHAN LUDWIG obtained his PhD in 1993 at the Institute of Virology of University of Giessen, Germany. After the Habilitation (2000) in Molecular Biology at the Julius-Maximilians-Universität Würzburg, he was research assistant at the Institute of Virology, University of Giessen (1993-1994). In 1995 he became group leader at the Institute for Medical Radiation and Cell Research (MSZ), University of Wuerzburg, from 2001 to 2002 he earned a senior research fellowship at the MSZ. Stephan Ludwig was University Professor at the Institute of Molecular Medicine (IMM), University of Duesseldorf (2002-2004). Since 2004 he is University Professor and Director at the Institute for Molecular Virology (IMV) at the Center for Molecular Biology of Inflammation (ZMBE), University of Muenster. He was Managing Director of ZMBE  from 2006-2008 and Vice-Rector for Research at the University of Muenster from 2009-2016. He coordinates several research networks, such as the nationwide influenza research network “FluResearchNet” (since 2007; initiated and supported by the German Ministry for Education an Research – BMBF) and the “National Research Platform for Zoonoses ” (since 2009; initiated and supported by the BMBF). The Research at the Institute of Molecular Virology focusses on intracellular signal transduction pathways and their impact on viral infection and inflammation with a major interest for influenza viruses. Via gathering knowledge about the cellular processes which control virus replication and inflammatory responses, his work aims at identifying novel strategies against infectious and inflammatory diseases.

THOMAS MERTENS studied Chemistry in Bonn and Medicine in Cologne (1968-1976). He obtained the MD Thesis (Dr. med.) on 1976 and his Habilitation on 1984. Thomas Mertens was medical assistant, training in internal medicine and surgery (1976–1977); he continued with a research fellowship for the postdoctoral training in immunology, virology and diagnostics, Institute of Virology, University of Cologne (1977–1985). In 1983 he reached the Board Certification in Microbiology and Epidemiology of Infectious Diseases. In 1985 he became Professor (C2) at the Institute of Virology, University of Cologne, from 1991 to 1998 he was Professor (C3), in the Dept. of Virology, Ulm University. He was Temporary Director of the Dept. Medical Hygiene, Ulm University Hospital from 1991 to 1992; and Dean of Studies at the Medical Faculty, Ulm University from 2003 to 2006. Since 1998 he is the Director of the Institute of Virology at the Ulm University Hospital. His research focuses: mechanisms of resistance of antiviral substances towards herpes viruses; the analysis of the biological function of the viral gene UL97; new targets for antiviral interference against human cytomegalovirus (HCMV); molecular mechanisms and functional relevance of host-cell genes modulation by HCMV; viral tegument proteins and Morphogenesis of HCMV; new organ culture model for analysis of HCMV infection; the characterization and function of G-protein coupled receptor homologs of HCMV; and the Clinical Virology.

GIORGIO PALÙ received his M.D. degree from the University of Padova (1973) and the Specialty diplomas in Oncology (1976) and General Pathology (1978) from the University of Pavia. He worked as a Postdoctoral Fellow and Research Associate at the Tumor Institute, Jules Bordet, Université Libre, Bruxelles (1975), the Chester Beatty Research Institute-Royal Marsden Hospital, Royal Cancer Institute, London University, UK (1976-79), the Department of Pharmacology, Yale University, New Haven, CT (1980).Assistant Professor in Microbiology, University of Parma (1980-82); Associate Professor in Virology, University of Padova (1983-1989); Visiting Professor, Department of Molecular Biochemistry and Biophysics, Yale University, 1982,1984,1986; Division of Virology, National Institute for Medical Research, Mill Hill, London, UK, 1980,1985,1987; Division of Human Retrovirology, Dana Farber Cancer Institute, Harvard Medical School (1990), Full Professor of Microbiology and Virology (since 1989), University of Padova. Director at the University of Padova: Institute of Microbiology (1991-1999); Department of Histology, Microbiology and Medical Biotechnologies, (1999-2002); Department of Molecular Medicine (since 2012); Head of the Padova GMP Cell-factory and of the Unit of Clinical Microbiology and Virology, Padova University Hospital (since 1996). Coordinator, PhD Course/School in Virology (since 1998) and in Biomedicine (since 2007); Member of the Board of the International PhD Programmes in Molecular Medicine, University of Ulm, Germany (since 2008), in Biomedicine and Translational Neurosciences, Temple University, Philadelphia, USA (since 2011); Adjunct Professor at the Medical School and at the Faculty of Sciences, University of Temple; Pro-Rector, University of Padova (2002-2004); Dean, Faculty of Medicine, University of Padova (2004-2011). GP has also served as a member of the scientific-technical Committee of the Italian Drug Agency (AIFA), of the directory Board of the Italian AIDS Commission, of the Istituto Superiore di Sanità (Rome) and of the Institute of Human Virology (Baltimore). Professor Palù is the running President of the European Society for Virology. Giorgio Palù has long-standing experience in the study of pathogenesis of viral infections and the design of viral and non-viral vectors for gene transfer, somatic gene therapy and vaccinology. He has made relevant contributions to the study of antimicrobial therapy and resistance and anticancer therapy with more than 400 publications and 10 patents. His basic research has provided a platform for finding new targets for antiviral therapy and new antivirals based on peptides and small molecules able to disrupt the interface of protein-protein interactions essential for viral replication.

VINCENZO SUMMA  Head of Chemistry  IRBM Science Park spa from February 2010. IRBM Science Park is a research centre formally a spin-off of the Merck Research Laboratories locate in Rome. He graduated in  Chemistry at Università degli Studi di Roma ‘La Sapienza’ in 1991 and in 1996 obtained his Ph.D in Organich Chemistry at Bergische Universität Wuppertal. From 1992 to 1994  was researcher at University of Rome “La Sapienza” . He became Research Fellow Merck  from  March 1996 to  August 2001 . Here was promoted Senior Research Fellow (September 2001 );Senior Investigator Merck  (November 2005 ) and Director in the medicinal chemistry department  from November 2007to October 2009. From June 2010 is  Associate Researcher CNR-ITB National Research Council – Institute for Biomedical Technologies and from April 2013  Member of the Board of Directors at CNCCS Consortium (IRBM SP – Consiglio Nazionale delle Ricerche – Istituto Superiore di Sanità)

 

IAAASS 2016 Participants

 IAAASS 2016 Participants  Commenti disabilitati su IAAASS 2016 Participants
Nov 292017
 

 

iaaass_24

Adibah AhamadBahtiar University Kebangsaan, Malaysia
Francesca Ambrosio Magna GraeciaUniversity, Italy
Marcin Biesiada Polish Academy of Sciences,Poland
Gloria Bua University of Bologna, Italy
Marta Cadeddu University of Cagliari, Italy
Jackson Chiei-His Taipei MedicalUniversity, Taiwan
Ilaria Conti University of Bologna, Italy
Angela Corona University of Cagliari, Italy
Luca Daino University of Cagliari, Italy
Jenny De University of Perugia, Italy
Simona Distinto  University of Cagliari, Italy
Francesca Esposito University of Cagliari, Italy
Lorena Fallarino University of Padova, Italy
Elisa Fanunza University of Cagliari, Italy
Tiago Figueira Universidade de Lisboa, Portugal
Aldo Frau University of Cagliari, Italy
Asier Gómez-SanJuan Instituto de Química Médica, Spain
Nicole Grandi University of Cagliari, Italy
Anastasia Khandazhinskaya EIMB RAS Moscow, Russia
Anna Korovina Russian Academy of Sciences, Russia
Chia-Lin Li Taipei MedicalUniversity, Taiwan
Fang-Yu Liang Taipei MedicalUniversity, Taiwan
Yi-Tzu Lin Taipei MedicalUniversity, Taiwan
Ching-Hsuan Liu Taipei MedicalUniversity, Taiwan
Yipeng Ma KU Leuven, Belgium
Valentina N.Madia University La Sapienza, Italy
Belén Martínez  Gualda  Instituto de Química Médica, Spain
Elena Matyugina EIMB RAS Moscow, Russia
Rita Meleddu University of Cagliari, Italy
Barbara Mertens Rega Institute, KU Leuven
Sara Pautasso University of Torino, Italy
Grazia Pavia Magna GraeciaUniversity, Italy
Maria Paola Pisano Pisano University of Cagliari,Italy
Hezha Rasul University of Sulaimani, Iraq
Isabella Romeo Magna GraeciaUniversity, Italy
Yuriy Rud Institute of Fisheries ofthe
Elisa Saccon University of Padova, Italy
Francesco Saladini University of Siena, Italy
Alessandra Scano University of Cagliari, Italy
Łukasz Świątek Medical University of Lublin,Poland
Joanna Sztuba-Solinska CCR NCI,Frederick, MD,USA
Maria ElenaTerlizzi University of Turin,Italy
Iuni Trist University of Siena, Italy
Carla Usai Universidad de Navarra, Spain
Elena Valletta University of Rome Tor Vergata, Italy
Pieter Vrijens Rega Institute for Medical Research, Belgium

IAAASS 2016 Speakers

 IAAASS 2016 Speakers  Commenti disabilitati su IAAASS 2016 Speakers
Nov 292017
 

CONFIRMED SPEAKERS

Stefano AlcaroSTEFANO ALCARO (*1966) obtained his doctoral degree in Pharmacology, Pharmacognosy and Toxicology at the Università La Sapienza di Roma. After his PhD he continued with a postdoctoral fellowship in the laboratory of Computional Chemistry of the Department of Chemistry at the Columbia University, New York (Prof. W. Clark Still team). On 1996 he has got his first permanent position as Medicinal Chemistry researcher at the Faculty of Pharmacy at the Università Magna Græcia of Catanzaro. From 2002 to 2011 he was Associate Professor in the same scientific sector (CHIM/08) at the University of Catanzaro. From 2011 he is Full Professor in the same academic institution. His main teaching course at the Università Magna Græcia of Catanzaro is Medicinal Chemistry and Toxicology I.
Stefano Alcaro is co-author of about 100 original publications on peer reviewed international journals, 4 books chapters, 2 international diffused volumes and over 100 national and international communications. His research interests are related to drug design and hit identification of bioactive compounds by means of computational methods especially in the fields of anticancer and antiviral therapies.

highlighted-article-november-12064515GRACIELA ANDREI holds a PhD in Biological Sciences and is an Assistant Professor at the Faculty of Medicine, Katholieke Universiteit Leuven, Belgium. At the Rega Institute for Medical Research, Department of Microbiology and Immunology, she carries out her research work that is mainly focused on chemotherapy of viral diseases, with emphasis on herpesviruses (cytomegalovirus, varicella-zoster virus and herpes simplex), poxviruses (vaccinia, cowpox, orf), polyomaviruses and papillomaviruses, and the study of the molecular mechanisms underlying the antiviral drug resistance phenomenon and anticancer activity of nucleotide analogues. Dr. G. Andrei has authored approximately 30 and co-authored approximately 260 papers in international peer-reviewed journals between 1983 and 2011. She has also (co)authored 6 book chapters and 10 proceedings articles and about 260 published abstracts between 1983 and 2011.

MAURIZIO BOTTA graduated with honors in chemistry at the University of Rome in 1974. After his military service he returned to work at the Institute of Organic Chemistry, University of Rome with the title of Fellow , under the guidance of Prof. R. Nicoletti . In 1977 he started at the University of New Brunswick (Canada) , a period of research under the guidance of Prof. K. Wiesner , earning his PhD in November 1979 . Since December 1979 resumed scientific and educational cooperation with Prof. R. Nicoletti at the University of Rome becoming a researcher . Winner of a bag NATO in 1985, he traveled for a year in laboratories of Prof. S. Hanessian of the ‘ University of Montreal (Canada) , as invited researcher .In October 1987 as an Associate Professor of Pharmaceutical Chemistry , he has held the chair of Analysis Pharmaceutical Chemistry III of the Degree Course in Pharmaceutical Chemistry and Technology of Faculty of Pharmacy, University of Siena and Bioorganic Chemistry for substitution at the Faculty of Mathematical, Physical and Natural Sciences. In the periods July-September 1987 – July September 1988 and from November to January 1989 he was Invited Professor at the University of Montreal (Canada). Since 2000 he is Full Professor of Pharmaceutical Chemistry at the University of Siena and holds the task of teaching Complements of Medicinal Chemistry and Synthesis and Design of Drugs for the Master of Science in Pharmaceutical Chemistry , University of Siena. In years 2002-2008 he held the position of Director of the Department of Drug Chemistry and Technology University of Siena. Prof. Botta was a member of the Board of the Division of Pharmaceutical Chemistry Society Italian Chemical from 1998 to 2004 , Director of the School ‘s annual ” Laboratory Methods Synthetic Medicinal Chemistry ” organizer of the workshop ” European Workshop on Drug  Design ” , now in its seventh edition and ‘ ” European Workshop in Drug Synthesis ” , at the University of Siena and he  is also a member of ‘ editorial board of scientific journals such as ” ChemMedChem ” , “Current Pharmaceutical Design” and ” Journal of Medicinal Chemistry ” . Since January 2008 he is Adjunct Professor at Temple University ‘s College of Science and Technology in Philadelphia (USA). The research group of Prof. Botta, currently consists of about 30 young people between undergraduates , graduate students,research grant and a single researcher , is active in the synthesis and structure determination of biologically active natural products , organic synthesis and testing of potential agents anti-viral and anti-cancer , anti-tuberculosis and synthesis of antifungal compounds . The techniques used to these studies can be summarized in conventional techniques for organic synthesis , synthesis techniques for small molecules in the solid phase , the use of enzymes , microwaves , and parallel synthesis, also  molecular modeling techniques , such as docking , molecular dynamics , QSAR and 3D QSAR Virtual screening , generation of virtual libraries are used for the discovery and optimization of potential drugs . Recently, next to the chemical synthesis and Computational has also added the analytical chemistry for the determination of parameters Pharmacokinetic necessary for the optimization of pharmacologically active molecules . The scientific production of Professor Botta is summed up in about 460 publications in journals International , 15 patents and more than 150 conference papers .

brayMIKE BRAY has had a nearly 30-year career in virology and antiviral drug development. After training in medicine and pathology and working as a forensic pathologist, he began research on dengue virus at the National Institutes of Health in 1986. In 1995, he transferred to the US Army Medical Research Institute of Infectious Diseases at Fort Detrick, where he studied hemorrhagic fever virus and poxvirus infections in laboratory animals and assessed new drugs and vaccines. In 2002, he returned to the NIH, where he is a medical officer in the Division of Clinical Research, NIAID. He served as the reviews editor of Antiviral Research from 2007-11, and became editor-in-chief in January, 2012

 CamarasaMARIA JOSÉ CAMARASA  obtained her PhD In Chemistry by the Universidad Complutense of Madrid. She was Head of the Chemotherapy Department of IQM-CSIC; Vice-Director of Medicinal Chemistry Institute (IQM-CSIC); President of the Spanish Society of Medicinal Chemistry (SEQT) (2004-2007); member of the executive board of the Chemistry Area of ANEP (2005-2008), coordinator of Medicinal Chemistry. She is actually Research Professor (Full professor) at the Medicinal Chemistry Institute of CSIC (IQM-CSIC), Madrid, Spain; co-coordinator of the Chemical Science and Technologies area of the CSIC; Head the of nucleosides and analogues group and Member of the executive board of International Society for Nucleosides, Nucleotides and Nucleic Acids (IS3Na). She was awarded in 2001 with the prestigious René Descartes-Prize of the European Commission. Her research interests are the Medicinal Chemistry, drug-design and discovery, antivirals, anticancer, antiinfectives, pro-drugs, organic chemistry, carbohydrates, nucleosi(ti)des, peptides.

Josè EstéJOSE ESTE is a Senior Researcher of the AIDS Research Institute-IrsiCaixa, Hospital Germans Trias i Pujol in Badalona (Barcelona), Spain and Head of the HIV Pathogenesis Laboratory. He received a BSc. degree in Biology from University of Western Ontario, a Masters degree in Biochemistry from the Venezuelan Institute of Scientific Research and a PhD degree from the Katholieke Universiteit Leuven. In 1997 he moved to his current post where he is leading his research group. Jose’s research interests include virus-cell interactions, HIV entry, antiviral drug-resistance and antiviral drug design and evaluation. José Esté has coauthored over 160 peer-reviewed publications and review articles and serves in different Spanish and international review boards and evaluation committees. He is the President of the International Society for Antiviral Research and editor of Antiviral Research.

HarrisREUBEN HARRIS is a Professor in the Biochemistry, Molecular Biology and Biophysics department, an Associate Director of the Institute of Molecular Virology, and a Member of the Masonic Cancer Center. He received his B.S. (1993) and Ph.D. (1997) degrees from the University of Alberta in Edmonton, Canada. He performed postdoctoral work at the Baylor College of Medicine (1997-8), at Yale University (1998), and at the Medical Research Council Laboratory of Molecular Biology (1998-2003). He joined the University of Minnesota as an Assistant Professor in the summer of 2003, became a tenured Associate Professor in 2008, and was promoted to Full Professor in 2013. As a Postdoctoral Fellow in Cambridge working with Dr. Michael Neuberger, Dr. Harris discovered a family of cellular enzymes that catalyze the conversion of the DNA base cytosine into the RNA base uracil. One member of this family is essential for generating antibody diversity (adaptive immunity) and several combine to provide protection from a wide variety of parasitic elements such as HIV (innate immunity). At least one member also becomes dyregulated in multiple human cancers and provides a major source of mutations. Dr. Harris has done pioneering studies in all of these important areas, thus far publishing over 100 manuscripts, filing 10 patents, and co-founding a company. He continues to run an academic research laboratory with multiple projects focused on the roles of these enzymes in immunity and carcinogenesis.

RobJordan_SmallROBERT JORDAN is Director of Biology at Gilead Sciences, Inc. He received his Ph.D. in Biochemistry from the Johns Hopkins University and completed postdoctoral training at Harvard University with Priscilla Schaffer studying herpesviruses. Prior to joining Gilead, Robert worked as an assistant professor at the University of Pennsylvania and then at Thomas Jefferson University before moving to industry, first at Viropharma Inc, and then Siga Technologies, where he co-discovered and developed Tecovirimat (ST-246), a novel, clinical stage, orthopoxvirus (smallpox) egress inhibitor, that was purchased by the U.S. government for inclusion in the strategic national stockpile. Since joining Gilead in 2011, Robert’s research has focused on discovery and development of antiviral compounds for treatment of acute virus infections that include respiratory viruses and emerging viruses. Robert has contributed to the development of Presatovir (GS-5806) that is in phase 2 clinical development for treatment of RSV infection and GS-5734, a clinical stage compound for treatment of ebolavirus disease.

Le griceSTUART LE GRICE received his Ph.D. from the Department of Biochemistry, University of Manchester, UK, in 1976, where he studied the mechanisms of R-factor-mediated multidrug resistance in Escherichia coli. After postdoctoral training in the United Kingdom, Germany, and the United States, he was appointed Senior Scientist in the Central Research Units of Hoffmann La Roche, Basel, Switzerland, where he worked from 1984 to 1990 evaluating HIV-1 and HIV-2 enzymes as therapeutic targets. In 1990, he joined the faculty in the Division of Infectious Diseases, Department of Medicine, Case Western Reserve University (CWRU), Cleveland, OH. Initially recruited as an Associate Professor of Medicine, he was awarded tenure in 1992, and in 1995 was promoted to Professor of Medicine, Biochemistry, and Oncology. From 1994 to 1999, he served as Director of the NIH-funded CWRU Center for AIDS Research. Dr. Le Grice joined the National Cancer Institute in 1999 as Chief of the Resistance Mechanisms Laboratory in the HIV Drug Resistance Program, Center for Cancer Research (CCR), and in 2005 was appointed to the Senior Biomedical Research Service. In 2006, he was appointed Head of the Center of Excellence in HIV/AIDS & Cancer Virology, CCR. He is a member of the CCR HIV and Cancer Virology faculty, Chemistry and Biology faculty, and the Steering Committee of the Molecular Targets Discovery Program. In addition to serving on the Editorial Board of the Journal of Biological Chemistry, Dr. Le Grice has been an ad hoc (1990-1999) and permanent Study Section member of NIH AIDS review panels (2000-2004), as well as an ad hoc reviewer for several international funding agencies.

MertensTHOMAS MERTENS studied Chemistry in Bonn and Medicine in Cologne (1968-1976). He obtained the MD Thesis (Dr. med.) on 1976 and his Habilitation on 1984. Thomas Mertens was medical assistant, training in internal medicine and surgery (1976–1977); he continued with a research fellowship for the postdoctoral training in immunology, virology and diagnostics, Institute of Virology, University of Cologne (1977–1985). In 1983 he reached the Board Certification in Microbiology and Epidemiology of Infectious Diseases. In 1985 he became Professor (C2) at the Institute of Virology, University of Cologne, from 1991 to 1998 he was Professor (C3), in the Dept. of Virology, Ulm University. He was Temporary Director of the Dept. Medical Hygiene, Ulm University Hospital from 1991 to 1992; and Dean of Studies at the Medical Faculty, Ulm University from 2003 to 2006. Since 1998 he is the Director of the Institute of Virology at the Ulm University Hospital. His research focuses: mechanisms of resistance of antiviral substances towards herpes viruses; the analysis of the biological function of the viral gene UL97; new targets for antiviral interference against human cytomegalovirus (HCMV); molecular mechanisms and functional relevance of host-cell genes modulation by HCMV; viral tegument proteins and Morphogenesis of HCMV; new organ culture model for analysis of HCMV infection; the characterization and function of G-protein coupled receptor homologs of HCMV; and the Clinical Virology.

imageGIORGIO PALÙ received his M.D. degree from the University of Padova (1973) and the Specialty diplomas in Oncology (1976) and General Pathology (1978) from the University of Pavia. He worked as a Postdoctoral Fellow and Research Associate at the Tumor Institute, Jules Bordet, Université Libre, Bruxelles (1975), the Chester Beatty Research Institute-Royal Marsden Hospital, Royal Cancer Institute, London University, UK (1976-79), the Department of Pharmacology, Yale University, New Haven, CT (1980).Assistant Professor in Microbiology, University of Parma (1980-82); Associate Professor in Virology, University of Padova (1983-1989); Visiting Professor, Department of Molecular Biochemistry and Biophysics, Yale University, 1982,1984,1986; Division of Virology, National Institute for Medical Research, Mill Hill, London, UK, 1980,1985,1987; Division of Human Retrovirology, Dana Farber Cancer Institute, Harvard Medical School (1990), Full Professor of Microbiology and Virology (since 1989), University of Padova. Director at the University of Padova: Institute of Microbiology (1991-1999); Department of Histology, Microbiology and Medical Biotechnologies, (1999-2002); Department of Molecular Medicine (since 2012); Head of the Padova GMP Cell-factory and of the Unit of Clinical Microbiology and Virology, Padova University Hospital (since 1996). Coordinator, PhD Course/School in Virology (since 1998) and in Biomedicine (since 2007); Member of the Board of the International PhD Programmes in Molecular Medicine, University of Ulm, Germany (since 2008), in Biomedicine and Translational Neurosciences, Temple University, Philadelphia, USA (since 2011); Adjunct Professor at the Medical School and at the Faculty of Sciences, University of Temple; Pro-Rector, University of Padova (2002-2004); Dean, Faculty of Medicine, University of Padova (2004-2011). GP has also served as a member of the scientific-technical Committee of the Italian Drug Agency (AIFA), of the directory Board of the Italian AIDS Commission, of the Istituto Superiore di Sanità (Rome) and of the Institute of Human Virology (Baltimore). Professor Palù is the running President of the European Society for Virology. Giorgio Palù has long-standing experience in the study of pathogenesis of viral infections and the design of viral and non-viral vectors for gene transfer, somatic gene therapy and vaccinology. He has made relevant contributions to the study of antimicrobial therapy and resistance and anticancer therapy with more than 400 publications and 10 patents. His basic research has provided a platform for finding new targets for antiviral therapy and new antivirals based on peptides and small molecules able to disrupt the interface of protein-protein interactions essential for viral replication.

Anna PapaANNA PAPA is Professor of Microbiology in the Dept. of Microbiology, Medical School, Aristotle University of Thessaloniki and Head of Hellenic Reference Centre for Arboviruses, Greece.She is the current President of the Hellenic Society of Virology, Secretary of the International Society for Hantaviruses, and member of the Editorial Board of Antiviral Research.Dr. Papa received her medical degree from Aristotle University of Thessaloniki and has been specialized in Microbiology. In the 1985 became Biopathologist at the Hospital of IKA, Thessaloniki, Greece, and in 2002: Senior scientist at the Dept. of Microbiology, Medical School, Aristotle University of Thessaloniki (main field: hemorrhagic fevers) and at the National AIDS Reference Laboratory of Northern Greece;  From 2002-today she is Head of Molecular Diagnostics and Special Viral Pathogens lab.  and Head of the National Reference Centre for Arboviruses. In the 2002 she became  Assistant Professor and in 2008 Associate Professor. Her highly active scientific activity is done in collaboration with the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA, at the Special Pathogens Department, Division of Viral and Rickettsial Diseases. Central Public Health Laboratory of London, UK. Haartman Institute, University of Helsinki, Finland. Robert-Nocht Institute for Tropical Medicine, Hamburg, Germany. Karolinska Institute, Stockholm, Sweden Collaboration also with laboratories in Albania, Bulgaria, Serbia, Czech Republic.Dr. Papa has published 180 scientific articles, most of them on emerging infectious diseases. Her research focuses on the diagnostics, discovery of novel viral strains, immune response and molecular epidemiology of arboviruses, mainly West Nile virus, Crimean-Congo hemorrhagic fever virus and phleboviruses. She collaborates with several scientific groups in Europe and US, and is partner of several EU projects.

KJPurzyckaKATARZYNA PURZYCKA earned her Bachelor Degree in Chemistry from the Poznan University in Poland in 2004. In 2009 she was awarded her PhD in Biochemistry from the Institute of Bioorganic Chemistry, Polish Academy of Sciences, where she studied HIV-2 RNA and its nucleoprotein complexes as potential therapeutic targets. She continued her studies on retroviral RNAs during her postdoctoral training at the National Cancer Institute, NIH, USA. In 2012 she was appointed Assistant Professor of Biochemistry at the Institute of Bioorganic Chemistry, Polish Academy of Sciences, where she is now head of the Retroelements’ Structure and Function Laboratory. DrPurzycka was a visiting professor at the University of Georgia, USA and she is a recipient of several awards, including MNiSW fellowship for outstanding young scientist. Her major scientific interests are RNA structural elements and transitions on both 2D and 3D structural levels that specify RNA functions at different stages of retrovirus and endogenous retrovirus-like retrotransposon replication.

SCHNEIDER JJOEL SCHNEIDER.As Professor of Chemistry and Biochemistry at the University of Delaware, Joel Schneider was recruited in 2010 to the National Cancer Institute (NCI), National Institutes of Health to serve as Chief of the newly-established Chemical Biology Laboratory. He has developed an internationally recognized multidisciplinary Laboratory whose core mission is to discover and apply chemical methods, tools, and materials to define and manipulate biological processes that impact cancer and AIDS. He has also established a Chemical Synthesis program within the Center for Cancer Research to aid non-chemist investigators within the NCI in the preparation of molecular probes and potential therapeutics. In his independent research, Dr. Schneider is developing novel biomaterials for use in parenteral delivery of therapeutics, tissue regeneration, and antibacterial therapy. His work has produced over 85 publications, multiple patents and over 160 invited lectures. He also serves as scientific mentor to young scientists, having trained a cadre of Ph.D. students and postdoctoral fellows who have taken key positions in both industry and academia. Dr. Schneider also serves as Deputy Director of the Center for Cancer Research, NCI.

summaVINCENZO SUMMA  Head of Chemistry  IRBM Science Park spa from February 2010. IRBM Science Park is a research centre formally a spin-off of the Merck Research Laboratories locate in Rome. He graduated in  Chemistry at Università degli Studi di Roma ‘La Sapienza’ in 1991 and in 1996 obtained his Ph.D in Organich Chemistry at Bergische Universität Wuppertal. From 1992 to 1994  was researcher at University of Rome “La Sapienza” . He became Research Fellow Merck  from  March 1996 to  August 2001 . Here was promoted Senior Research Fellow (September 2001 );Senior Investigator Merck  (November 2005 ) and Director in the medicinal chemistry department  from November 2007to October 2009. From June 2010 is  Associate Researcher CNR-ITB National Research Council – Institute for Biomedical Technologies and from April 2013  Member of the Board of Directors at CNCCS Consortium (IRBM SP – Consiglio Nazionale delle Ricerche – Istituto Superiore di Sanità)

REGISTRATION

 IAAASS 2012 Home  Commenti disabilitati su REGISTRATION
Gen 292016
 

A nominal registration fee of 250 € will be charged to offset administrative costs. Registration fees also cover accommodation and meals.

The submission deadline for all applications is

June 30th 2014.

Each applicant must submit the application form with personal data, education, professional experiences and an abstract for a short talk or a poster presentation. The Organizing Committee will review each application form and notify the applicant of their admission to the Summer School by July 30th . Accepted applicants will be required to complete their registration form not later than September 6.

Application forms can be visualized and downloaded here. Filled applications should be uploaded and submitted using the form below:
[contact-form-7]
The Organizing Committee will review each registration form and notify the applicant of their admission to the Summer School by August 31 2014. Accepted applicants will be required to complete their registration form not later than September 6 2014.

In case of special needs please feel free to contact us at: iaaass@unica.it

IAAASS 2014 Program

 IAAASS 2014 program  Commenti disabilitati su IAAASS 2014 Program
Gen 282016
 

September 28 – October 3, 2014 

2014.09.28

 6.00 pm                                     Registration

7.00 pm

Inaugural Lecture

 Enzo Tramontano                 Summer School welcoming remarks

Giorgio Palù                             President of the European Society for Virology welcoming                                                                                                         remarks

Carlo Federico Perno           Introduction to Inaugural Lecture

Jan Balzarini                           Carbohydrate binding agents: novel therapeutic concept as                                                                                                       selective antiviral compounds.

8.30 pm                                     Dinner

 2014.09.29                                    

9.00 am

Plenary lectures

Chairman: Cristina Parolin

Stephan Becker                      Identifying targets for antifiloviral interventions

Maurizio Botta                        Design, synthesis and biological evaluation of human DDX3                                                                                                    inhibitors with multiple antiviral activities

11.00-11.15am                   Coffee break

11.15 am

Chairman: Stuart Le Grice

Eric Freed                                 Development of potent and broadly active HIV-1 maturation                                                                                                     inhibitors

Giorgio Palù                             Different approaches to develop effective antiviral strategies

1.00 pm                               Lunch

3.30-5.00 pm                     Discussion groups

5.00-6.00 pm                          Coffee break – Poster session I

6.00-7.15 pm

Student talks

Chairman:  Elias Maccioni

Florencia Linero                    Isolation and characterization of Nanobodies against Junin                                                                                                    virus as new and improved treatment option for Argentine                                                                                                        hemorrhagic fever

Serena Massari                       Targeting Influenza A Virus RNA-dependent-RNA-                                                                                                                     polymerase: development of PA/PB1 interaction inhibitors

Finny Varghese                      Novel antivirals affecting Alphaviruses, including the re-                                                                                                           emerging Chikungunya virus

Marta Cadeddu                       Identification and characterization of HERV-K (HML-10) in                                                                                                    GRCh37/hg19  assembly and their possible association with                                                                                                      the human diseases

Pouya Hassandavish            Mechanism study of baicalein activity against dengue virus                                                                                                       replication

8.00 pm                                    Dinner

2014.09.30                                   

9.00 am

Plenary lectures

Chairman: Giorgio Palù

Le Grice Stuart                        Therapeutic Targeting of the Retroviral RNA Genome

Mátyus Péter                           Through hardships to the drug candidate (Per aspera ad                                                                                                              astra) – old and new concepts in HIV drug discovery

11.00-11.15am                   Coffee Break

11.15 am

Chairman: Eric Freed

Thomas Mertens                   Mechanisms, clinical problems and management of resistance                                                                                                 against herpesvirus infections

Birgitta Wöhrl                         Inhibition of Foamy Virus RNase H by HIV-1 RNase H                                                                                                                inhibitors  development of a model system

1.00 pm                              Lunch

3.30-5.00 pm                     Discussion groups

5.00-6.00 pm                          Coffee break – Poster session II

6.00-7.15 pm

Student talks

Chairman:  Maurizio Botta

St. Patrick Reid                       The lipid kinase sphingosine kinase 2 is an essential host                                                                                                            factor  recruited by Chikungunya virus during infection

Agharbaoui Fatima E           From natural products to HIV-1 IN/LEDGF interaction                                                                                                               inhibitors:computational and synthetic approaches

Michele Celestino                  Unrevealing the molecular mechanisms accounting for the                                                                                                        FIV envelope glycoprotein ability to overcome feline tetherin                                                                                                   restriction

Valeria Cannas                       Identification of VP35 dsRNA binding pocket useful residues                                                                                                     for development of small-molecules inhibitors against Ebola                                                                                                     virus

Łukasz Świątek                       Antiviral activity of leaves and cones of Alnus sieboldiana                                                                                                         Matsum against HHV-1

8.00 pm                                    Dinner

2014.10.01                                    

 9.00 am

Plenary lectures

Chairman: Jan Balzarini

Reuben Harris                        The Biological and Pathological Importance of Enzyme-                                                                                                            Catalyzed  DNA Cytosine Deamination

Federico Gago                         Structure-based computational strategies in the design of                                                                                                          antiviral  drugs

 11.00-11.15am                   Coffee Break

11.15 am

Chairman: Thomas Mertens

Kvaratskhelia Mamuka       Multimerization selective inhibitors of HIV-1 integrase

Enzo Tramontano                 Are human endogenous retroviruses possible drug targets?

 1.00 pm                              Lunch

Free afternoon

8.00 pm                                    Dinner

2014.10.02                                    

 9.00 am

Plenary lectures

Chairman: Stephan Becker

Ben Berkhout                          New anti-HIV approaches: peptide inhibitors, RNAi gene                                                                                                          therapy and the humanized mouse model for drug testing

Maccioni Elias                        Drug design: principles and considerations

11.00-11.15am                   Coffee Break

11.15 am

Round table on “Working in a company after the PhD”

Chairman: Stuart Le Grice

Participant: Franco Lori and Vincenzo Summa

1.00 pm                              Lunch

3.00-4.30 pm                     Discussion groups

4.30-5.00  pm                   Coffee Break

 5.00-7.00 pm

Plenary lectures

Chairman: Reuben Harris

Roberto Di Santo                   Inhibiting the HIV Integration Process: Past, Present, and the                                                                                                 Future

Camarasa María José           gp120 as a target of the design and discovery of HIV-                                                                                                                 entry/fusion inhibitors 

8.00 pm                                    Social Dinner

2014.10.03                                    

 Breakfast and leaving

ACCORDO DI COOPERAZIONE CON LA TAIPEI MEDICAL UNIVERSITY

 Senza categoria  Commenti disabilitati su ACCORDO DI COOPERAZIONE CON LA TAIPEI MEDICAL UNIVERSITY
Mag 072015
 

Cagliari, 4 maggio 2015 – Il prof. Enzo Tramontano, delegato dell’Università di Cagliari, ed il prof. Yun Yen Presidente della Taipei Medical University hanno firmato a Taipei (Taiwan) un accordo di cooperazione tra i due atenei per sviluppare progetti di ricerca congiunti e permettere lo scambio di studenti e professori tra la due Università.

 
La Taipei Medical University (http://www.tmu.edu.tw/english/main.php) è stata fondata nel 1960, e nel 2014 si è classificata al 95mo posto nella categoria Life Science & Medicine, e al 379mo posto tra tutti gli Atenei nel QS World University ranking.
E’ organizzata in 7 College (Facoltà) e 3 Ospedali di ricerca con seimila studenti di cui 500 esteri, suddivisi in 12 programmi per undergraduate e 23 per postgraduated, e può contare su uno staff di 550 docenti.
Il prof. Tramontano ha poi incontrato i Prorettori ai Rapporti Internazionali e alla Ricerca e Sviluppo, i Presidi dei College of Pharmacy e College of Medicine della Taipei Medical University e ha tenuto due seminari rivolti agli studenti relativi ai suoi studi sui virus Ebola e HIV.
credits unica.it | accessibilità Università degli Studi di Cagliari
C.F.: 80019600925 - P.I.: 00443370929
note legali | privacy

Nascondi la toolbar